[Successful weaning from cardiopulmonary bypass with administration of landiolol hydrochloride in a patient with hypertrophic obstructive cardiomyopathy].
A 14-yr-old boy with hypertrophic obstructive cardiomyopathy, undergoing percutaneous transluminal septal myocardial ablation suffered dissection of the left main coronary artery during the procedure. Sixty minutes after absolute ethanol administration, he was transferred to the operating room for emergency coronary artery bypass grafting, mitral valve replacement and cardiomyectomy. Transesophageal echocardiography (TEE) findings after the induction of anesthesia were: general hypokinesis, mitral regurgitation 1+, left ventricular outflow tract pressure gradient of 11 mmHg and no blood flow in the left anterior descending coronary artery. On aorta declamping, ECG showed ventricular fibrillation and ventricular tachycardia, and the sinus rhythm was restored after 100 mg lidocaine i.v. and DC conversion. TEE revealed severe hypokinesis in antero-septal and hypokinesis in posterolateral wall, respectively. Since supraventricular tachycardia (HR 130 140 bpm) disabled the intraaortic balloon pump (IABP) synchronization, HR was maintained 90-100 bpm with landiolol hydrochloride (10-40 micrograms x kg(-1) min(-1)) and synchronization was obtained. Systolic BP was maintained 90-120 mmHg with norepinephrine (0.2-0.3 micrograms x kg(-1) x min(-1)) and the patient could be successfully weaned from CPB with cardiac index 2.0 and mixed venous oxygen saturation 59%. On the 2nd postoperative day (POD), he was weaned from IABP and ventilator. On the 6 th POD, he was discharged from the ICU.
Shinzawa
Masahide
M
Department of Anesthesiology, National Cardiovascular Center, Suita.
Nohmi
Toshihiro
T
Tsuzuki
Masanobu
M
Ohnishi
Yoshihiko
Y
Kuro
Masakazu
M
D000293:Adolescent; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D002312:Cardiomyopathy, Hypertrophic / Q000628:therapy*; D002315:Cardiopulmonary Bypass; D017115:Catheter Ablation; D006801:Humans; D007423:Intra-Aortic Balloon Pumping; D008297:Male; D009025:Morpholines / Q000627:therapeutic use*; D014508:Urea / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D009025:Morpholines; C077049:landiolol; D014508:Urea